CRISPR-Cas9: Revolutionizing the Genetic Frontier

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 03 | 02 | Page :
    By

    Ms. Khushi Yuvraj Patil,

  • Mr. Akash S. Jain,

  • Mr. Divakar R. Patil,

  • Mr. Azam Z. Shaikh,

  • Mr. Sameer Shaikh,

  • Dr. S. P. Pawar,

  1. B. Pharm student, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  2. Associate Professor, Department of Pharmaceutics, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada,, Maharashtra, India
  3. Associate Professor, Department of Pharmaceutics, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  4. Associate Professor, Department of Pharmaceutics, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada,, Maharashtra, India
  5. Associate Professor, Department of Pharmaceutics, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  6. Principal, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India

Abstract

The rapid development of CRISPR/CRISPR-associated enzyme (Cas) technology has enabled truly customised treatment of human genetic disorders, paving the way for recent developments in the field of gene therapy. Because CRISPR/Cas can accurately target and edit individual genes within a genome, it has established itself as a formidable tool for genetic manipulation.  CRISPR/Cas9 technology allows for precise editing of specific DNA sequences in an organism’s genome. This method uses three key components: the target DNA, a guide RNA that directs the editing machinery to the correct location, and the Cas9 enzyme, which makes a cut at the desired site in the DNA. This two-component system, consisting of the guide RNA and Cas9 enzyme, provides an efficient and straightforward approach to gene editing. CRISPR/Cas9 is becoming into a potent tool for high throughput target gene screening in cancer treatment. Genome editing using CRISPR/Cas9 technologies has becoming more and more popular. Building on these foundational principles, CRISPR/Cas9 technology has rapidly evolved to become a cornerstone in the study and treatment of genetic diseases. Its ability to precisely target DNA sequences enables researchers to correct mutations that cause hereditary disorders, offering hope for cures where none previously existed. Beyond its therapeutic applications, CRISPR is widely used in basic research to understand gene function and regulation. Scientists employ this tool to knock out or modify genes in various organisms, which accelerates discoveries in biology and medicine. Moreover, the simplicity and cost-effectiveness of CRISPR/Cas9 compared to previous gene-editing technologies have democratized genetic engineering, making it accessible to a broader range of laboratories worldwide. This democratization has led to an explosion of innovative research and clinical trials exploring new ways to combat diseases such as cancer, HIV, and genetic blindness. Despite these advances, ethical and safety considerations remain critical in the development and application of CRISPR technology. Researchers are actively working to refine the specificity of CRISPR/Cas9 to minimize off-target effects and ensure long-term safety in patients. As these challenges are addressed, CRISPR’s potential to revolutionize medicine and biotechnology continues to grow exponentially, promising a future where genetic diseases can be precisely treated or even prevented altogether.

Keywords: CRISPR, gene therapy, iPSCs, NHEJ pathway, HDR pathway

How to cite this article:
Ms. Khushi Yuvraj Patil, Mr. Akash S. Jain, Mr. Divakar R. Patil, Mr. Azam Z. Shaikh, Mr. Sameer Shaikh, Dr. S. P. Pawar. CRISPR-Cas9: Revolutionizing the Genetic Frontier. International Journal of Genetic Modifications and Recombinations. 2025; 03(02):-.
How to cite this URL:
Ms. Khushi Yuvraj Patil, Mr. Akash S. Jain, Mr. Divakar R. Patil, Mr. Azam Z. Shaikh, Mr. Sameer Shaikh, Dr. S. P. Pawar. CRISPR-Cas9: Revolutionizing the Genetic Frontier. International Journal of Genetic Modifications and Recombinations. 2025; 03(02):-. Available from: https://journals.stmjournals.com/ijgmr/article=2025/view=228344


References

  1. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901-10
  2. Humbert O, Davis L, Maizels N. Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol. (2012) 47:264–81. doi: 10.3109/10409238.2012.658112
  3. Teng, Y. Yao, V. Nair, and J. Luo, “Latest Advances of Virology Research Using Crispr/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development, Viruses (2021):779, https:// doi.org/10.3390/v13050779.
  4. Misra S. Human gene therapy: a brief overview of the genetic revolution. J Assoc Physicians India. 2013;61(2):127-33. Review.
  5. Marraffini LA, Sontheimer EJ. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet. 2010;11(3):181-90. Review
  6. Ishino, Y. et al. Nucleotide sequence of the gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169, 5429–5433 (1987).
  7. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-21
  8. 8.Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012). Cas9‐crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences of the United States of America, 109, E2579–E2586
  9. CongL, ZhangF.Genomeengineering using CRISPR-Cas9 system. Methods Mol Biol. (2015) :197–217. doi: 10.1007/978-1-4939-1862-1_10
  10. Ceasar SA, Rajan V, Prykhozhij SV, Berman JN, Ignacimuthu S. Insert, remove or replace: a highly advanced genome editing system using CRISPR/Cas9. Biochim Biophys Acta Mol Cell. 2016;1863(9):2333–2344. doi:10.1016 /j. bbamcr.2016.06.009
  11. Kundar and K. Gokarn, “CRISPR Cas System: A Tool to Eliminate Drug-Resistant Gram-Negative Bacteria,” Pharmaceuticals 15, no. 12 (2022): 1498, https://doi.org/10.3390/ph15121498
  12. Baylis F, Mcleod M. First-in-human phase 1 CRISPR gene editing cancer trials: are we ready? Curr Gene Ther. (2017) 17:309–19. doi: 10.2174/1566523217666171121165935
  13. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood. (2011) 118:19–27. doi: 10.1182/blood-2011-03-325258
  14. Maeder ML, Stefanidakis M, Wilson CJ, Baral R, Barrera LA, Bounoutas GS, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. (2019) 25:229–33. doi: 10.1038/s41591-018-0327-9
  15. Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z, et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection.
  16. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrobial Agents. (2020) 55:105955. Doi: 10.1016/j.ijantimicag.2020.105955
  17. Kang Y, Chu C, Wang F, Niu Y (2019) CRISPR/Cas9-mediated genome editing in nonhuman primates. Dis Models Mech 12(10): dmm 03998
  18. Dampier, W., Nonnemacher, M. R., Sullivan, N. T., Jacobson, J. M., & Wigdahl, B. (2014). HIV excision utilizing CRISPR/Cas9 technology: Attacking the proviral quasispecies in reservoirs to achieve a cure.
  19. Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015). Proprotein convertase subtilisin/kexin type 9 inhibition. Circulation, 132, 1648–1666.
  20. Daiger, S. P., Bowne, S. J., & Sullivan, L. S. (2007). Perspective on genes and mutations causing retinitis pigmentosa. Archives of Ophthalmology (Chicago, Ill.: 1960), 125, 151–158
  21. 21.Kumar P, Malik YS, Ganesh B, Rahangdale S, Saurabh S, Natesan S, Dhama K (2020) CRISPR Cas system: An approach with potentials for COVID-19 diagnosis and therapeutics. Front Cell Infect Microbiol 10:576875
  22. Isgrò A., Gaziev J., Sodani P., Lucarelli G. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Ann. N. Y. Acad. Sci.
  23. Cho S.W., Kim S., Kim Y., Kweon J., Kim H.S., Bae S., Kim J.-S. Analysis of off-target effects of CRISPR/Cas-Derived RNA-guided endonucleases and nickases. Genome Res. 2014; 24:132–141. doi: 10.1101/gr.162339.113.
  24. Caplan A.L., Parent B., Shen M., Plunkett C. No time to waste—the ethical challenges created by CRISPR. EMBO Rep. 201516:1421–1426. doi: 10.15252/embr.201541337.
  25. Furtado R.N., Furtado R.N. Gene Editing: The risks and benefits of modifying human DNA. Rev. Bioética. 2019; 27:223–233. doi: 10.1590/1983-80422019272304.
  26. Li C, Brant E, Budak H, et al. CRISPR/Cas: A Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement. J Zhejiang Univ Sci B. 2021;22(4):253–84.
  27. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372):eaan4672. doi:10.1126/science.aan4672.
Ahead of Print Subscription Review Article
Volume 03
02
Received 07/06/2025
Accepted 14/08/2025
Published 29/09/2025
Publication Time 114 Days
179

Login


My IP

PlumX Metrics